Depomed Announces Fourth Quarter and Full Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
Depomed (DEPO) Tops Q4 EPS by 5c
February 27, 2018 4:04 PM ESTDepomed (NASDAQ: DEPO) reported Q4 EPS of $0.15, $0.05 better than the analyst estimate of $0.10. Revenue for the quarter came in at $94 million versus the consensus estimate of $90.94 million.
For earnings history and earnings-related data on Depomed (DEPO) click here.
... More


